摘要
目的分析瑞舒伐他汀和阿托伐他汀对缺血性脑卒中患者血脂水平及颈动脉粥样硬化的改善效果。方法在我院2013年12月至2016年12月实施治疗的缺血性脑卒中患者中随机选取120例,依照患者临床治疗方式分成两组,分别实施瑞舒伐他汀(瑞舒伐他汀组)和阿托伐他汀(阿托伐他汀组)治疗,比较分析两组患者治疗前、后的血脂水平及颈动脉粥样硬化改善效果。结果治疗后,两组患者的LDL-C水平和治疗前相比明显降低(P<0.05),且瑞舒伐他汀组低于阿托伐他汀组(P<0.05);治疗后,两组患者的颈动脉IMT较治疗前均有一定程度的下降,但组内、组间差异均无统计学意义(P>0.05)。结论在缺血性脑卒中患者的临床治疗过程中,采用瑞舒伐他汀和阿托伐他汀治疗的效果差别不大,可以依照患者的实际需求选择相应的治疗方式。
Objective To evaluate the effect improvement of rosuvastatin and atorvastatin on blood lipid levels and atherosclerosis in patients with ischemic stroke. Methods One hundred and twenty cases of patients with ischemic stroke in our hospital from December 2013 to December 2016 were selected and divided into two groups according to the treatment methods, which were treated with rosuvastatin(rosuvastatin group) and atorvastatin(atorvastatin group) respectively, with 60 cases in each group. Then the levels of blood lipid and carotid atherosclerosis improvement were compared between the two groups before and after the treatment. Results After treatment, LDL-C levels in both groups were significantly lower than before treatment(P〈0.05), and that of the rosuvastatin group was lower than the atorvastatin group(P〈0.05). After treatment,the carotid IMT of the two groups had a slight decrease compared with those before treatment, there was no significant difference(P〉0.05), and there was no significant difference between the two groups(P〉0.05). Conclusion In the clinical treatment of ischemic stroke, rosuvastatin and atorvastatin have little difference in clinical effects, and the appropriate treatment method can be chosen according to the actual needs of patients.
出处
《临床医学研究与实践》
2017年第33期32-33,共2页
Clinical Research and Practice